|
|
2600 Stemmons Freeway, Suite 176
Dallas, TX 75207-2107 USA
phone:(214) 905-5100
fax:(214) 905-5101
|
| Symbol |
ACCP |
| Exchange |
OTC |
| Founded |
1995 |
| Employees |
11 |
|
|
| www.accesspharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| A biopharmaceutical company that develops products for the care of cancer patients. |
|
| Management |
| Jeffrey B. Davis, CEO;
Phillip Wise, VP Business Development;
David Nowotnik, CSO;
Stephen Thompson, CFO;
Frank Jacobucci, VP Marketing |
|
|
|
|
| Keywords |
| synthetic polymer-targeted delivery, vitamin-mediated targeted delivery, vitamin-mediated oral delivery, bioerodible hydrogel technology, nanoparticles and nanoparticle networks, hydrogel particle aggregate technology, Residerm topical delivery, carbohydrate, cancer, ACCP |
|
|
|
|
| Description |
|
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technologies based on the natural vitamin B12 uptake mechanisms and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com. |
|
| Products / Services |
MuGard - FDA-approved for management of oral mucositis; ProLindac - proprietary DACH platinum chemotherapy; Thiarabine - proprietary nucleoside analogue for leukemia/lymphoma; Cobalamin oral drug and targeted drug delivery platforms.
|
|
| Technology / Differentiation |
| Polymer Chemistry; drug delivery technology; cobalamin oral drug delivery; cobalamin targeted drug delivery; |
|
| Market / Customers |
Global pharma market
|
|
| Competitors / Substitutes / Alternatives |
Biovail Corporation, Bristol-Myers Squibb Co., Endo Pharmaceuticals Holdings Inc.
|
|
| Status |
| Approved, Phase 2, preclinical |
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
